NCT06586437 Neuromodulation of the Cortex and Spinal Cord
| NCT ID | NCT06586437 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Father Flanagan's Boys' Home |
| Condition | Cerebral Palsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-01-17 |
| Primary Completion | 2029-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-01-17 with a primary completion date of 2029-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Specific Aim 1: To further quantify the difference in the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence of persons with CP. Overall hypotheses: The sensorimotor cortical activity, spinal cord activity, and corticospinal coherence will be uncharacteristic in persons with CP when compared with neurotypical controls. Furthermore, the extent of the alterations in the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence will be tightly linked with the clinical presentations of persons with CP. Specific Aim 2: To investigate the effect of transcutaneous current stimulation applied over the cortex and/or spinal cord on the sensorimotor cortical activity, spinal cord dynamics, and corticospinal coherence. Overall hypotheses: Compared with the sham controls, those receiving the transcutaneous current stimulation will demonstrate alterations in the strength of the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence. Moreover, the extent of the alterations in the sensorimotor cortical activity, spinal cord activity, and corticospinal coherence will be tightly linked with the clinical presentations of persons with CP.
Eligibility Criteria
Inclusion Criteria: * For Cerebral Palsy Participants: * Gross Motor Function Classification score (GMFCS) levels between I-IV * For Neurotypical Controls: * No known atypical neurodevelopment (e.g. autism, Down Syndrome, ADHD, etc.) Exclusion Criteria: * For Cerebral Palsy Participants: * Pregnancy * Any condition that, in the opinion of the investigator, is a contraindication to participation * The presence of any ferrous metal implant, including orthodonture, which may interfere with the MEG data acquisition and/or be an MRI safety concern * No orthopedic surgery in the last 6 months or metal in their body that would preclude the use of an MRI * For Neurotypical Controls: Pregnancy * Any condition that, in the opinion of the investigator, is a contraindication to participation * The presence of any ferrous metal implant, including orthodonture, which may interfere with the MEG data acquisition and/or be an MRI safety concern * No orthopedic surgery in the last 6 months or metal in their body that would preclude the use of an MRI
Contact & Investigator
Max J Kurz, PhD
PRINCIPAL INVESTIGATOR
Father Flanagan's Boys' Home
Frequently Asked Questions
Who can join the NCT06586437 clinical trial?
This trial is open to participants of all sexes, aged 11 Years or older, up to 45 Years, studying Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06586437 currently recruiting?
Yes, NCT06586437 is actively recruiting participants. Contact the research team at max.kurz@boystown.org for enrollment information.
Where is the NCT06586437 trial being conducted?
This trial is being conducted at Boys Town, United States.
Who is sponsoring the NCT06586437 clinical trial?
NCT06586437 is sponsored by Father Flanagan's Boys' Home. The principal investigator is Max J Kurz, PhD at Father Flanagan's Boys' Home. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.